Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nicardipine
Drug ID BADD_D01560
Description A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
Indications and Usage Used for the management of patients with chronic stable angina and for the treatment of hypertension.
Marketing Status approved; investigational
ATC Code C08CA04
DrugBank ID DB00622
KEGG ID D08270
MeSH ID D009529
PubChem ID 4474
TTD Drug ID D0T0KA
NDC Product Code Not Available
UNII CZ5312222S
Synonyms Nicardipine | Cardene | Vasonase | Antagonil | Cardene SR | Dagan | Flusemide | Lecibral | Lincil | Loxen | Lucenfal | Nicardipine Hydrochloride | Hydrochloride, Nicardipine | Nicardipine LA | LA, Nicardipine | Nicardipino Ratiopharm | Perdipine | Ridene | Y-93 | Y 93 | Y93 | Cardene I.V. | Nicardipino Seid
Chemical Information
Molecular Formula C26H29N3O6
CAS Registry Number 55985-32-5
SMILES CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal pain07.01.05.005--
Haematuria24.07.01.047; 20.02.01.006; 21.10.01.018--
Haemorrhage intracranial24.07.04.003; 17.08.01.008--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertonia15.05.04.007; 17.05.02.001--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypokalaemia14.05.03.002--
Hypophosphataemia14.04.03.001--
Hypotension24.06.03.002--
Infection11.01.08.002--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Menopausal symptoms21.02.02.002--Not Available
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nervousness19.06.02.003--Not Available
Nocturia20.02.03.001--Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Oxygen saturation decreased13.02.01.004--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages